Related Experiment Video
Updated: May 29, 2026

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract
Published on: July 1, 2020
Update on invasive fungal disease
1Instituto di Ematologica, Università Cattolica del Sacro Cuore, Largo Francesco Vita, 1, I-00168, Rome, Italy. lpagano@rm.unicatt.it
The first European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guideline for Candida diseases was presented. Experts also discussed antifungal therapy for invasive fungal disease in intensive care and hematological malignancy patients.
Area of Science:
- Clinical Microbiology
- Infectious Diseases
- Antifungal Therapy
Background:
- Antifungal resistance and invasive fungal infections pose significant challenges in clinical settings.
- There is a need for updated guidelines to manage complex fungal diseases.
Purpose of the Study:
- To present the first ESCMID guideline for the diagnosis and management of Candida diseases.
- To discuss current strategies for invasive fungal disease management in critical care and hematology.
Main Methods:
- Presentation of the newly developed ESCMID guideline.
- Discussion of clinical data from new studies and real-world experience.
- Expert-led sessions focusing on specific patient populations.
Main Results:
- The release of the first ESCMID guideline for Candida diseases.
- Insights into antifungal strategies for intensive care unit and hematological malignancy patients.
- Presentation of new clinical data and real-life antifungal therapy experiences.
Conclusions:
- The new ESCMID guideline provides a framework for Candida disease management.
- Current antifungal approaches for high-risk patient groups were reviewed.
- Evidence from clinical studies and real-world data informs antifungal therapy choices.
Related Concept Videos
Cryptococcal Meningitis
Antifungal Agents
Endocarditis III: Medical Management
Fungal Phylum Microsporidia
Candidiasis
Endocarditis IV: Nursing Management
